1. Introduction {#sec1}
===============

Aspirin and ADP receptor antagonists represent an unquestionable strategy for patients undergoing percutaneous coronary intervention (PCI), both for stable and unstable coronary disease \[[@B1]\]. High on-treatment platelet reactivity (HOPR), variously defined and analyzed, has been reported in up to 30% of these patients \[[@B2]\] and has been linked to adverse cardiac events at follow-up \[[@B3]--[@B6]\].

Due to the high prevalence of HOPR and the assumption that HOPR increases the risk of adverse cardiac events, randomized clinical trials were performed to test the safety and efficacy of a tailored strategy (defined as an increase in dose or a switch to another ADP receptor antagonist) in patients undergoing PCI. When appraised separately, most of these studies were negative, without achieving the expected reduction in recurrent thrombotic events \[[@B7]--[@B9]\].

Prognostic impact of HOPR was assessed by at least two meta-analyses, although limited from methodological flaws \[[@B3], [@B4]\], due to lack of adjustement for baseline differences in burden of traditional risk factors and clinical presentation, which may explain themselves the increased risk of adverse cardiac events in selected patients. These two studies, however, have not tested the independent clinical effect of inadequate platelet inhibition on outcomes; moreover they evaluated patients with different risk profiles (ACS and stable angina) and different treatments (aspirin together with ADP antagonists or periprocedural glycoprotein inhibitors \[[@B10], [@B11]\]).

Randomisation of patients to HOPR and non-HOPR groups is obviously not feasible; consequently a bias analysis may help to elucidate the impact of HOPR on clinical prognosis independently from cardiovascular risk factors and clinical presentations.

2. Methods {#sec2}
==========

The recent Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) amendment to the Quality of Reporting of Meta-analyses (QUOROM) statement, and recommendations from The Cochrane Collaboration and Meta-analysis of Observational Studies in Epidemiology (MOOSE) were followed during the development of the present systematic review \[[@B11]--[@B16]\].

2.1. Search Strategy and Study Selection {#sec2.1}
----------------------------------------

Pertinent articles were searched in Medline, Cochrane Library, Biomed Central, and Google Scholar in keeping with established methods with MESH strategy and with the following terms: (Prognosis/Broad\[filter\]) AND (platelet \* AND (reactivity OR aggregation OR activation OR response \*) AND (death OR (myocardial AND infarction))). Three independent reviewers (Fabrizio D\'Ascenzo, Umberto Barbero, and Marta Bisi) screened the retrieved citations via the title and/or abstract; divergences were resolved via consensus. If potentially pertinent, studies were then appraised as complete reports according to the following explicit selection criteria. Studies were included if (i) reporting more than 50 patients (ii) independent prognostic impact of HOPR evaluated through multivariate analysis, while exclusion criteria were (i) nonhuman setting, (ii) duplicate reporting (in which case the manuscript reporting the largest sample of patients was selected), and (iii) interventional studies.

2.2. Data Extraction, End Points, and Sensitivity Analysis {#sec2.2}
----------------------------------------------------------

Three unblinded independent reviewers (Fabrizio D\'Ascenzo, Umberto Barbero, and Marta Bisi) abstracted the following data on prespecified forms: authors, journal, year of publication, location of the study group, and baseline clinical and interventional features. Data extraction was conducted by mutual agreement and all potential disagreement was solved by consensus. Incidence of adverse cardiac events (all-cause mortality and cardiovascular mortality, nonfatal myocardial infarction and stroke, and revascularization and stent thrombosis) was the primary end point. Sensitivity analyses were performed appraising aspirin and ADP receptor antagonists separately. Similarly we appraise indications for PCI in stable and unstable disease (i.e., either unstable angina, ST and non-ST segment elevation myocardial infarction). Finally, we analyze all-cause death, stent thrombosis and major bleedings.

2.3. Internal Validity and Quality Appraisal {#sec2.3}
--------------------------------------------

Unblinded independent reviewers (Fabrizio D\'Ascenzo, Umberto Barbero, and Marta Bisi) evaluated quality of included studies on prespecified forms. Modifying the MOOSE items to take into account the specific features of included studies \[[@B11]\], we separately abstracted and appraised study design, setting, and data source, as well as risk of analytical, selection, adjudication, detection, and attrition bias (expressed as low, moderate, or high risk of bias, as well as incomplete reporting leading to inability to ascertain the underlying risk of bias).

2.4. Data Analysis and Synthesis {#sec2.4}
--------------------------------

Continuous variables are reported as mean (standard deviation) or median (interquartile). Categorical variables are expressed as *n*/*N* (%). Statistical pooling was performed according to a random-effect model with generic inverse-variance weighting, computing risk estimates with 95% confidence intervals, using RevMan 5 (The Cochrane Collaboration, The Nordic Cochrane Centre, Copenhagen, Denmark), and Comprehensive Meta-Analysis. Metaregression analysis was performed to identify impact of length of follow-up on results. Small study bias was appraised by graphical inspection of funnel plots and formally through Begg and Mazumdar rank correlation, Egger\'s regression intercept, and Duval and Tweedie trim and fill \[[@B14]\].

3. Results {#sec3}
==========

2189 records were identified through database searching, and 38 were appraised at text level and finally twenty-six studies (see Appendix) were included ([Figure 1](#fig1){ref-type="fig"}) including 28.178 patients. The median age was 66.8 (64--68), with 22.7% (22.4--27.8) being female. Diabetes mellitus, hypertension, hyperlipidemia, and a history of previous MI were reported in 29% (24.2--34), 84% (58.9--89), 70% (54.4--71), and 30% (18--39), respectively. Stable angina was the admission diagnosis for 45% (37--100) of patients, ACS for 45% (33--100), and AMI for 12% (0--34). HOPR on aspirin was reported in 25% (22--26) of population, 29% (25--37) for patients on ADP receptor antagonists, and 26% (22--39) for both (Tables [1](#tab1){ref-type="table"}, [2](#tab2){ref-type="table"}, and [3](#tab3){ref-type="table"}). After a median follow-up of 1 year (0.1--1), adverse cardiac events occurred in 8.3% (3--11) of patients. Pooling all studies together, HOPR significantly increased the risk of adverse cardiac events (OR 1.33 \[95% CI: 1.09, 1.64\], *I* ^2^ 0%, [Figure 2](#fig2){ref-type="fig"}). At metaregression analysis, length of follow up did not influence these results (Beta −0.001, *P* 0.58). HOPR did not increase risk of death (OR 1.13 \[0.96, 1.33\], *I* ^2^ 0%), of stent thrombosis (OR 1.25 \[0.87, 1.78\], *I* ^2^ 0%), and of major bleedings (1.20 \[0.93, 1.56\], *I* ^2^ 21%, [Figure 3](#fig3){ref-type="fig"}).

Sensitivity analysis for diagnosis showed that HOPR did not increase the risk of adverse cardiac events for patients with ACS (1.06 \[0.79, 1.43\], *I* ^2^ = 0%), AMI (0.95 \[0.61, 1.46\], *I* ^2^ = 0%), or stable angina (1.16 \[0.82, 1.63\], *I* ^2^ = 0%, [Figure 4](#fig4){ref-type="fig"}).

Sensitivity analysis according to type of antiplatelet medication indicated that neither was HOPR an independent predictor of adverse cardiac events, nor did this show if patients were resistant to aspirin, ADP antagonists (clopidogrel in all studies), or both (1.16 \[0.93, 1.45\], *I* ^2^ = 0%; 1.09 \[0.93, 1.28\], *I* ^2^ = 0%; and 1.26 \[0.70, 2.27\], *I* ^2^ = 0%, [Figure 5](#fig5){ref-type="fig"}).

For all studies, publication bias was graphically evident ([Figure 6](#fig6){ref-type="fig"}) and formally assessed with Begg and Mazumdar rank correlation (with a positive Tau of 0.31) and with Egger\'s regression intercept (Intercept 0.42 : 0.11--0.69; *t*-value 2.81). After adjusting for this bias with Duval and Tweedie trim and fill, HOPR was not a significant prognostic indicator for all studies (OR 1.1 : 0.89--1.22, *I* ^2^ 0%; trim and fill methods evaluate publication bias by evaluating number of "asymmetric" trials on the right side, removing and replacing them with missing counterparts at the pooled estimate, and evaluating the adjusted confidence interval \[[@B14]\]).

4. Discussion {#sec4}
=============

The main results of the present meta-analysis, investigating incidence and impact of HOPR on prognosis, are as follows: (a) HOPR represents a frequent finding for patients with coronary artery disease, both in chronic and acute settings; (b) current evidence is limited from relevant publication bias; (c) after adjustment for clinical and methodological confounders HOPR appraised for "all comers" with CAD does not significantly increase the hazard of adverse cardiac events; and (d) usefulness in high-risk patients may not be excluded and remains to be assessed.

Many reasons can explain nonresponsiveness to antiplatelet medications, such as interindividual variability in the metabolism of clopidogrel (which is a prodrug activated by CYP-3A4, CYP-2C19, and CYP1A2), drug-drug interactions (i.e., interaction on the same metabolic pathway for clopidogrel, but also competition for binding sites on COX-1 by nonsteroidal anti-inflammatory medications and aspirin), P2Y12 receptor polymorphisms and increased platelet turnover during inflammation, acute coronary events, and diabetes mellitus. Interestingly, conventional cardiovascular risk factors themselves (smoking, diabetes, and hyperlipidemia) and also the same clinical pattern of unstable angina, increasing macrophage\'s thromboxane synthesis, enhance resistance to aspirin \[[@B17]\].

Previously, numerous observational studies have demonstrated the causal relationship between laboratory evidence of nonresponsiveness to aspirin or clopidogrel and an increase hazard of death, myocardial reinfarction, and stent thrombosis during secondary prevention for coronary disease \[[@B20], [@B23], [@B19], [@B18]--[@B22]\]. The obvious induction was that individualization of antiplatelet therapy based on laboratory tests should improve outcomes, even if most of these studies were limited by absence of multivariate adjustments, that is, without a global assessment of potential clinical confounders \[[@B23]\], for example, the presence of diabetes, which increases both HOPR and recurrent cardiac events after ACS.

However, subsequent randomized controlled trials questioned this hypothesis. In the ARMYDA-2 study, pretreatment with a 600 mg loading dose of clopidogrel given before PCI was demonstrated to be safe and, as compared with the 300-mg dose, reduced periprocedural MI without increased bleeding \[[@B24]\]. On the other hand, the GRAVITAS and the ARCTIC trials, which randomized patients with HOPR after PCI with drug eluting stents to high-dose clopidogrel compared with standard-dose, did not showe significant improvements in clinical outcomes \[[@B26], [@B25]\]. Later, new evidence suggested that a more tailored therapy could be attained by switching to newer drugs \[[@B9], [@B28], [@B29]\]. Similarly, randomized evidence failed to demonstrate a clinical impact. The TRIGGER-PCI study showed that HOPR after elective PCI with DES implantation, if detected, can be reliably corrected by switching from clopidogrel to prasugrel but again failed to demonstrate an improvement in clinical outcomes \[[@B31]\]. A similar result emerged from the TRILOGY-ACS trial, randomizing patients with NSTE-ACS who were medically managed \[[@B32]\]. More recently, switching to ticagrelor seems to be associated to an effective reduction in HOPR but studies about the effective clinical impact are still lacking \[[@B31], [@B33]\].

This meta-analysis indicates that HOPR does not seem to be a useful predictor of outcomes in an "all comers" CAD population. These results hold true both for overall studies, and, after appraisal for diagnosis, types of antiplatelet medication analysed and assays were exploited. These findings may be explained because they derive from data drawn from multivariate analysis, with a critical adjustment (even though limited by absence of randomization itself) for clinical features both increasing platelet resistance and risk of adverse events (like diabetes mellitus, smoking, or renal disease).

While HOPR should not totally be disregarded, a focus on high-risk patients seems more appropriate \[[@B33]--[@B37]\], for example, those with recurrent stent thrombosis in the absence of periprocedural or adherence problems or in diabetic or in HIV populations who have a well-known increased risk of recurrent events.

Current evidence remains burdened from relevant publication bias, which deeply affects clinical interpretation of HOPR. This phenomenon was described by psychologist Robert Rosenthal as the "file drawer problem\"; he wrote that "journals are filled with the 5% of the studies that show Type I errors, while the file drawers are filled with the 95% of the studies that show nonsignificant results" \[[@B38]\]. In the cardiovascular field, this problem was recently demonstrated by Ioannidis and colleagues \[[@B39]\], who stated that, among 56 meta-analyses reporting relationships between biomarkers and cardiovascular events, only 13 were not affected by selection bias. However, most of current guidelines do not include this kind of evaluation, which may deeply influence every day clinical decisions.

Our analysis has some limitations, including a great number of observational studies, which brings incomplete data around follow-up and about the correct reporting of adverse effects, different definitions, and outcomes. Moreover, for each sensitivity analysis, the number of patients was inferior to that of overall population, although superior or similar to that of previous meta-analysis on this topic \[[@B3], [@B4]\]. Again, just a small number of studies could reliably monitor compliance. Platelet reactivity tests differed in each study, which also limits the HOPR definition. Because of the selection criteria, no studies selected use the Platelet Vasodilator-Stimulated Phosphorylation test (PLT-VASP test), a flow cytometry test that is today the most specific test to assess the effect of the platelet P2Y12 antagonists (clopidogrel, ticlopidine, and prasugrel) \[[@B35]\]. Thus, the included studies\' quality was evaluated according to standardized criteria and we separately abstracted and appraised study design, setting, and data source, as well as risk of analytical, selection, adjudication, detection, and attrition bias. For all studies, publication bias was formally assessed. After adjusting for this bias, HOPR did not significantly increase adverse cardiac events for all studies.

We therefore conclude that routine assessment of HOPR is not useful, but high-risk subsets of patients (i.e., diabetics, multiple cardiovascular risk factors, and important comorbidities, especially if they need therapies potentially interacting with antiplatelet drugs) may potentially benefit from its assessment and interpretations remain to be assessed.

ACS:

:   Acute coronary syndrome

AMI:

:   Acute myocardial infarction

HOPR:

:   High on-treatment platelet reactivity

PCI:

:   Percutaneous coronary intervention.
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###### 

Baseline features of included studies.

                                                     Number of patients   Age           Female patients (%)   Diabetes mellitus (%)   Hypertension (%)   Hyperlipidemia (%)   Previous myocardial infarction (%)   Stable angina (%)   Acute coronary syndromes (%)   Myocardial infarction (%)
  -------------------------------------------------- -------------------- ------------- --------------------- ----------------------- ------------------ -------------------- ------------------------------------ ------------------- ------------------------------ ---------------------------
  Angiolillo et al., 2007 \[[@B41]\]                 173                  67 ± 9        35                    100                     65                 68                   53                                   100                 0                              0
  Bliden et al., 2007 \[[@B20]\]                     100                  66 ± 11       28                    44                      74                 83                   40                                   75                  13                             12
  Breet et al., 2010 \[[@B23]\]                      410                  64 ± 11.3     26.8                  17.3                    72.4               77.6                 58.3                                 100                 0                              0
  Breet et al., 2010 \[[@B23]\]                      920                  64 ± 10.6     24.6                  18.4                    77.5               80.9                 54.6                                 100                 0                              0
  Buonamici et al., 2007 \[[@B2]\]                   804                  69 ± 11       25                    21                      62                 50                   26                                   34                  39                             27
  Campo et al., 2010 \[[@B42]\]                      826                  68 ± 12       25.2                  24                      72.3               59.4                 38.6                                 64.4                35.6 (low risk UA)             ---
  Chiu et al., 2011 \[[@B43]\]                       144                  65 ± 10       24                    46.5                    68.8               50                   18                                   55                  45                             ---
  Collet et al., 2012 \[[@B7]\]                      106                  64 ± 10       23                    25                      58                 56                   46 (previous ACS)                    0                   100                            0
  Cuisset et al., 2006; 300 mg \[[@B26]\]            146                  64.2 ± 10.3   21                    29                      58                 56                   44 (previous ACS)                    0                   100                            100
  Cuisset et al., 2006; 600 mg \[[@B26]\]            146                  65.2 ± 12     27                    33                      56                 55                   45 (previous ACS)                    0                   100                            100
  Geisler et al., 2006 \[[@B19]\]                    379                  67.5 ± 10     26.9                  34.7                    79.6               60.6                 45.5 (previous ACS)                  54                  45                             ---
  Hochholzer et al., 2006 \[[@B46]\]                 802                  66.4 ± 9.1    21.8                  24.8                    82.3               nd                   22.9                                 100                 0                              0
  Jin et al., 2013 \[[@B47]\]                        181                  61.3 ± 12.1   16.6                  24.9                    39.5               95.5                 3.9                                  0                   100                            100
  D.-W. Park et al., 2011 \[[@B48]\]                 809                  64            33.2                  30.5                    66.3               45.4                 7.2                                  100                 ---                            ---
  Ko et al., 2011 \[[@B50]\]                         222                  63.3          31.5                  32.0                    72.1               46.8                 5.9                                  100                 ---                            ---
  Marcucci et al., 2012 \[[@B51]\]                   1187                 69            25.2                  24.0                    65.4               54.4                 x                                    ---                 100                            35
  Motoda et al., 2012 \[[@B52]\]                     450                  71.1          31.5                  42.8                    74.0               60.2                 31.1                                 100                 ---                            ---
  K. W. Park et al., 2011 \[[@B49]\]                 2546                 61.7          29.9                  28.5                    58.9               61.0                 5.9                                  55.6                44.4                           ---
  **Park et al. (ACS), 2013 \[[@B53]\]**             **1095**             **62**        **21**                **26**                  **60**             **58**               **5**                                **---**             **100**                        
  **Park et al. (Stable Angina), 2013 \[[@B53]\]**   **1329**             **63**        **22**                **27**                  **57**             **63**               **4**                                **100**             **0**                          **0**
  Parodi et al., 2011 \[[@B54]\]                     1789                 69            20                    19.8                    57.0               44.7                 18.1                                 ---                 100                            46
  Patti et al., 2008 \[[@B25]\]                      160                  66            19.3                  34.3                    nd                 74.3                 28.1                                 45.7                54.3                           ---
  Pettersen et al., 2012 \[[@B55]\]                  1001                 62.3          21.8                  20.0                    55.4               98.3                 43.7                                 100                 ---                            ---
  Price et al., 2011 \[[@B9]\]                       380                  68            23.2                  28.9                    88.2               35.5                 31.6                                 100                 ---                            ---
  Saia et al., 2013 \[[@B56]\]                       833                  67.6          25                    28.7                    69.3               67.5                 32.0                                 0                   0                              100
  Sibbing et al., 2009 \[[@B57]\]                    1608                 67.5          23.0                  29.0                    91.6               70.0                 32.0                                 66.9                33                             20
  Sibbing et al., 2012 \[[@B58]\]                    564                  67.7          22.3                  31.2                    89.3               70.5                 19.1                                 ---                 100                            100
  Siller-Matula et al., 2013 \[[@B59]\]              403                  64.2          24.1                  32.0                    84.6               76.4                 32.0                                 67                  33.0                           33.0
  **Stone et al., 2013 \[[@B60]\]**                  **8665**             **63.6**      **26**                **32.4**                **79.6**           **74.3**                                                  **48.3**            **27.6**                       **24.1**

###### 

Incidence of reactivity on aspirin, clopidogrel or both and kind of assays used.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                     Reactivity on aspirin and ADP receptor antagonists (%)   Reactivity on aspirin (%)   Reactivity on ADP receptor antagonists (%)   Assays used
  -------------------------------------------------- -------------------------------------------------------- --------------------------- -------------------------------------------- ------------------------------------------------------------------------------------------------------------------
  Angiolillo et al., 2007 \[[@B41]\]                 ---                                                      ---                         **25**                                       Light Transmittance Aggregometry (ADP 20 mmol/L-upper quartile)

  Bliden et al., 2007 \[[@B20]\]                     ---                                                      ---                         22 (LTA)\                                    Light Transmittance Aggregometry (ADP 5 mmol/L)\
                                                                                                                                          30 (TEG)                                     Thromboelastography

  Breet et al., 2010 \[[@B23]\]                      14.7                                                     8.5 (aspirin only)          25.1 (clopidogrel only)                      Verify Now aspirin/Verify Now P2Y12

  Breet et al., 2010 \[[@B23]\]                      26.9 (LTA 5)\                                            21.1 (LTA 5)\               14.9 (LTA 5)\                                Light Transmittance Aggregometry\
                                                     23.3 (LTA 20)                                            24.7 (LTA 20)               13.0 (LTA 20)                                (ADP 5 mmol/L-LTA 5, and 20 mmol/L-LTA 20)

  Buonamici et al., 2007 \[[@B2]\]                   ---                                                      ---                         13                                           Light Transmittance Aggregometry (ADP 10 mmol/L)

  Campo et al., 2010 \[[@B42]\]                      3                                                        15                          21.6                                         Verify Now aspirin/Verify Now P2Y12

  Chiu et al., 2011 \[[@B43]\]                       ---                                                      ---                         33                                           Platelet Function Analyzer-100

  Collet et al., 2012 \[[@B7]\]                      ---                                                      27                          26                                           Both ADP and arachidonic acid (AA) as agonists to explore the responses to clopidogrel and aspirin, respectively

  Cuisset et al., 2006; 300 mg \[[@B26]\]            ---                                                      ---                         25                                           Light Transmittance Aggregometry (ADP 10 mmol/L)

  Cuisset et al., 2006; 600 mg \[[@B26]\]            ---                                                      ---                         15                                           Light Transmittance Aggregometry (ADP 10 mmol/L)

  Geisler et al., 2006 \[[@B19]\]                    ---                                                      ---                         5.8                                          Light Transmittance Aggregometry (ADP 20 mmol/L)

  Hochholzer et al., 2006 \[[@B46]\]                 ---                                                      ---                         50                                           Verify Now P2Y 12

  Jin et al., 2013 \[[@B47]\]                        ---                                                      nd                          55                                           Multiple electrode aggregometry, Verify Now P2Y 12, Verify Now Aspirin

  D.-W. Park et al., 2011 \[[@B48]\]                 ---                                                      ---                         40.9                                         Light Transmittance Aggregometry (ADP 10 mmol/L)

  Ko et al., 2011 \[[@B50]\]                         52                                                       ---                         ---                                          ADP-induced platelet aggregation using a whole blood analyzer

  Marcucci et al., 2012 \[[@B51]\]                   11                                                       17                          44                                           Multiple electrode aggregometry

  Motoda et al., 2012 \[[@B52]\]                     ---                                                      ---                         50                                           Multiple electrode aggregometry

  K. W. Park et al., 2011 \[[@B49]\]                 ---                                                      ---                         25                                           Verify Now P2Y 12

  **Park et al. (ACS), 2013 \[[@B53]\]**                                                                                                  **63**                                       Verify Now P2Y 12

  **Park et al. (Stable Angina), 2013 \[[@B53]\]**                                                                                        **61**                                       Verify Now P2Y 12

  Parodi et al., 2011 \[[@B54]\]                     ---                                                      26                          ---                                          PFA 100

  Patti et al., 2008 \[[@B25]\]                      ---                                                      ---                         32.1                                         Verify Now P2Y 12

  Pettersen et al., 2012 \[[@B55]\]                  ---                                                      ---                         20                                           Multiple electrode aggregometry (ADP)

  Price et al., 2011 \[[@B9]\]                       ---                                                      ---                         36                                           Multiple electrode aggregometry (ADP)

  **Saia et al., 2013 \[[@B56]\]**                   **---**                                                  **---**                     **67**                                       **Verify Now P2Y12**

  Sibbing et al., 2009 \[[@B57]\]                    8                                                        27                          19                                           Multiple electrode aggregometry (AA and ADP)

  Sibbing et al., 2012 \[[@B58]\]                                                                                                                                                       

  Siller-Matula et al., 2013 \[[@B59]\]                                                                                                                                                 

  **Stone et al., 2013 \[[@B60]\]**                                                                                                       **42.7**                                     **Verify Now aspirin/Verify Now P2Y12**
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Incidence and definition of outcome appraised in the multivariate model.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
                                                     Follow-up (months)   Definition of outcome                                                                                       Incidence of outcome
  -------------------------------------------------- -------------------- ----------------------------------------------------------------------------------------------------------- --------------------------------
  Angiolillo et al., 2007 \[[@B41]\]                 24                   Cardiovascular death, ACS, and stroke                                                                       15.2 1st quartile

  12.2 2nd quartile                                                                                                                                                                   

  12.2 3rd quartile                                                                                                                                                                   

  37.7 4th quartile                                                                                                                                                                   

                                                                                                                                                                                      

  Bliden et al., 2007 \[[@B20]\]                     1\                   Death secondary to any cardiovascular cause, stroke,\                                                       23 (1 month FU)\
                                                     12                   myocardial infarction (ami), and target/nontarget vessel\                                                   50 (12 months FU)
                                                                          revascularization                                                                                           

                                                                                                                                                                                      

  Breet et al., 2010 \[[@B23]\]                      12                   All-cause death, nonfatal ami, stent thrombosis, and stroke                                                 LTA 5 11.3 (DHPR)

     8.8 (HAPR)                                                                                                                                                                       

     10.9 (HCPR)                                                                                                                                                                      

     4.1 (NPR)                                                                                                                                                                        

  LTA 20 10.7 (DHPR)                                                                                                                                                                  

     9.6 (HAPR)                                                                                                                                                                       

     11.7 (HCPR)                                                                                                                                                                      

     4.2 (NPR)                                                                                                                                                                        

                                                                                                                                                                                      

  Buonamici et al., 2007 \[[@B2]\]                   6                    Stent thrombosis                                                                                            3.1

                                                                                                                                                                                      

  Campo et al., 2010 \[[@B42]\]                      12                   All-cause death, nonfatal ami, and stroke                                                                   Full Responder (FR) 8.6

  Poor Responder (PR) 15.8                                                                                                                                                            

  ASA FR 10 PR 13                                                                                                                                                                     

  Clop FR 5.9 PR 17.3                                                                                                                                                                 

                                                                                                                                                                                      

  Chiu et al., 2011 \[[@B43]\]                       24                   Cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke                                    10

                                                                                                                                                                                      

  Collet et al., 2012 \[[@B7]\]                      1                    Stent thrombosis                                                                                            2

                                                                                                                                                                                      

  Cuisset et al., 2006; 300 mg \[[@B26]\]            1                    Cardiovascular death, nonfatal ami, stent thrombosis, and stroke                                            12

  33.3 HPR 0.5 NPR                                                                                                                                                                    

                                                                                                                                                                                      

  Cuisset et al., 2006; 600 mg \[[@B26]\]            1                    Cardiovascular death, nonfatal ami, stent thrombosis, and stroke                                            4.1

  27.2 HPR 0.008 NPR                                                                                                                                                                  

                                                                                                                                                                                      

  Geisler et al., 2006 \[[@B19]\]                    3                    Cardiovascular death, nonfatal ami, and nonfatal stroke                                                     6.6

  5.6 Adequate clopidogrel response                                                                                                                                                   

  22.7 Low clopidogrel response                                                                                                                                                       

                                                                                                                                                                                      

  Hochholzer et al., 2006 \[[@B46]\]                 1                    All-cause death, nonfatal ami, and percutaneous revascularization                                           1.9

  3.5 in upper quartile                                                                                                                                                               

                                                                                                                                                                                      

  Jin et al., 2013 \[[@B47]\]                        12                   Cardiovascular death, nonfatal ami, and nonfatal stroke                                                     11

                                                                                                                                                                                      

  D.-W. Park et al., 2011 \[[@B48]\]                 12                   Cardiac death and nonfatal ami                                                                              1.4

  0.9 Adequate clopidogrel response                                                                                                                                                   

  2.8 Low clopidogrel response                                                                                                                                                        

                                                                                                                                                                                      

  Ko et al., 2011 \[[@B50]\]                         1                    All-cause death, nonfatal ami, nonfatal stroke, and percutaneous revascularization                          8.6

                                                                                                                                                                                      

  Marcucci et al., 2012 \[[@B51]\]                   12                   Cardiac death and nonfatal ami                                                                              9.6

                                                                                                                                                                                      

  Motoda et al., 2012 \[[@B52]\]                     12                   Cardiac death, nonfatal ami, stent thrombosis, and target vessel revascularization                          12

  19 in HPR                                                                                                                                                                           

  5.1 in NPR                                                                                                                                                                          

                                                                                                                                                                                      

  K. W. Park et al., 2011 \[[@B49]\]                 24                   Cardiac death, nonfatal ami, nonfatal stroke, and urgent percutaneous revascularization                     14.6 HPR

  8.7 LPR                                                                                                                                                                             

                                                                                                                                                                                      

  **Park et al. (ACS), 2013 \[[@B53]\]**             72                   Cardiac death, nonfatal ami, nonfatal stroke, urgent percutaneous revascularization, and stent thrombosis    

                                                                                                                                                                                      

  **Park et al. (Stable Angina), 2013 \[[@B53]\]**   72                   Cardiac death, nonfatal ami, nonfatal stroke, urgent percutaneous revascularization, and stent thrombosis    

                                                                                                                                                                                      

  Parodi et al., 2011 \[[@B54]\]                     1                    Cardiac death, nonfatal ami and percutaneous revascularization                                              3 1st quartile

  5 2nd quartile                                                                                                                                                                      

  10 3rd quartile                                                                                                                                                                     

  20 4th quartile                                                                                                                                                                     

                                                                                                                                                                                      

  Patti et al., 2008 \[[@B25]\]                      24                   All-cause death, nonfatal ami, unstable angina, and stroke                                                  13.3 HAPR

  9.9 LAPR                                                                                                                                                                            

                                                                                                                                                                                      

  Pettersen et al., 2012 \[[@B55]\]                  6                    Cardiovascular death, nonfatal myocardial infarction, and stent thrombosis                                  6.5 HPR

  1 LPR                                                                                                                                                                               

                                                                                                                                                                                      

  Price et al., 2011 \[[@B9]\]                       1                    Stent thrombosis                                                                                            2.2 HPR

  0.2 LPR                                                                                                                                                                             

                                                                                                                                                                                      

  **Saia et al., 2013 \[[@B56]\]**                   **12**               **All-cause death, ami, and urgent target vessel revascularization**                                         

                                                                                                                                                                                      

  Sibbing et al., 2009 \[[@B57]\]                    1                    All-cause death, ami, and urgent target vessel revascularization                                            Abciximab/UFH: 9.4 HPR 6.7 LPR

  Bivalirudin: 22.0 HPR 5.0 LPR                                                                                                                                                       

                                                                                                                                                                                      

  Sibbing et al., 2012 \[[@B58]\]                    12                   Acute coronary syndrome, stent thrombosis, stroke, death, and revascularization                             37.5 DHPR

  33.3 HCPR                                                                                                                                                                           

  25.6 HAPR                                                                                                                                                                           

  18.6 LPR                                                                                                                                                                            

                                                                                                                                                                                      

  Siller-Matula et al., 2013 \[[@B59]\]                                   Acute coronary syndrome, stent thrombosis, stroke, death, and revascularization                              

                                                                                                                                                                                      

  **Stone et al., 2013 \[[@B60]\]**                  **24**               **All-cause death and myocardial infarction and stent thrombosis**                                          **2.4 death**

  **3.9 mi**                                                                                                                                                                          

  **1.3 ST**                                                                                                                                                                          
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

[^1]: Academic Editor: Ahmed Abdel-Latif
